<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088256</url>
  </required_header>
  <id_info>
    <org_study_id>Etoricox09-10</org_study_id>
    <secondary_id>2009-015496-27</secondary_id>
    <nct_id>NCT01088256</nct_id>
  </id_info>
  <brief_title>Efficacy of Etoricoxib on Peripheral Hyperalgesia</brief_title>
  <official_title>Efficacy of Etoricoxib in Patients With Neuropathic Pain With and Without Peripheral Hyperalgesia - A Prove of Concept Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruhr University of Bochum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the efficacy of etoricoxib on pain patients. The
      investigators assume that patients with neuropathic pain will have greater pain relief then
      patients on placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Animal experiments analysing anti-hyperalgesic effects of Coxibs show inconsistent results
      due to different used dosages and varying different pain models. Theoretical the use of
      NSAIDs is rational, particularly of Coxibs as a part of the neuropathic pain management. But
      in the newest topical review, there is no valid information available about the effectiveness
      of these drugs in human neuropathic pain models or in patients with different underlying
      mechanism, e.g. with or without hyperalgesia.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Superior improvement of peripheral hyperalgesia at day six after initiation of Cox-2-inhibiting-medication in comparison to placebo</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of the average on-going pain</measure>
    <time_frame>12 month</time_frame>
    <description>reduction of the average on-going pain decrease of the neuropathic symptoms intensity (NPSI score) decrease of the patients global impression of change (PGIC) decrease of the frequency and cumulative 7 day dosage of rescue medication</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Causalgia</condition>
  <condition>Polyneuropathy</condition>
  <condition>Postherpetic Neuralgia</condition>
  <condition>Peripheral Nerve Injury</condition>
  <condition>Radiculopathy</condition>
  <arm_group>
    <arm_group_label>etoricoxib, peripheral hyperalgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>14 patient with neuropathic pain and peripheral hyperalgesia get etoricoxib 90mg for 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etoricoxib, no peripheral hyperalgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>14 patients with neuropathic pain without peripheral hyperalgesia get etoricoxib 90mg for 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, peripheral hyperalgesia</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>14 patients with neuropathic pain with peripheral hyperalgesia get placebo for 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, no peripheral hyperalgesia</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>14 patients with neuropathic pain without peripheral hyperalgesia get placebo for 8 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib</intervention_name>
    <description>the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day</description>
    <arm_group_label>etoricoxib, peripheral hyperalgesia</arm_group_label>
    <arm_group_label>etoricoxib, no peripheral hyperalgesia</arm_group_label>
    <other_name>Arcoxia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>patients get one pill of placebo (sugar-pill) per day for 8 days.</description>
    <arm_group_label>placebo, peripheral hyperalgesia</arm_group_label>
    <arm_group_label>placebo, no peripheral hyperalgesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years with

          -  Persistent moderate or severe pain (&gt; 4 on NRS (1..10)) at rest (average of three
             daily assessments using a diary for at least two days) .

          -  Neuropathic pain associated with a clinical and neurologically proven peripheral nerve
             injury, radiculopathy, postherpetic neuralgia or polyneuropathy or CRPS

          -  One of the two following QST phenotypes at the baseline assessment:

               -  signs of peripheral hyperalgesia (that means, pathological decreased heat pain
                  threshold and/or pathological decreased muscle pain threshold)

               -  without signs of peripheral hyperalgesia (no pathological decreased heat - and/or
                  muscle pain threshold)

          -  Patients of both gender

          -  Signed consent form

          -  Patients with the ability to understand and follow the instructions of the doctor

        Exclusion Criteria:

          -  Excluded will be patients Parkinson's disease or a history of cerebral vascular insult
             or nerve injury.

        Excluded will be also all patients with contradictions for the use of Etoricoxib:

          -  Hypersensitivity to the active substance or to any of the excipients.

          -  Active peptic ulceration or active gastrointestinal (GI) bleeding.

          -  Patients who have experienced bronchospasm, acute rhinitis, nasal polyps,
             angioneurotic oedema, urticaria, or allergic-type reactions after taking
             acetyl-salicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.

          -  Pregnancy and lactation

          -  Severe hepatic dysfunction (serum albumin &lt;25 g/l or Child-Pugh score ≥10).

          -  Estimated renal creatinine clearance &lt;30 ml/min.

          -  Inflammatory bowel disease.

          -  Congestive heart failure (NYHA II-IV).

          -  Patients with hypertension whose blood pressure is persistently elevated above
             140/90mmHg and has not been adequately controlled

          -  Established ischemic heart disease, peripheral arterial disease, and/or
             cerebrovascular disease.

          -  Intake of one of the following drugs (current or in the last 3 days)

               -  selective-serotonin-reuptake-inhibitor

               -  cetoconazole

               -  rifampicin

               -  phenytoin

               -  carbamazepine

               -  dexamethasone or other systemic corticoids

               -  traditional nonsteroidal antiphlogistics

               -  cyclooxygenase-inhibitors

               -  immunosuppressives

               -  TNF-α-inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Maier, Dr.med</last_name>
    <role>Study Director</role>
    <affiliation>University hospital Bergmannsheil department of pain therapy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bergmannsheil department of pain therapy</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>August 23, 2012</last_update_submitted>
  <last_update_submitted_qc>August 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruhr University of Bochum</investigator_affiliation>
    <investigator_full_name>Christoph Maier, Prof. Dr.</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>CRPS</keyword>
  <keyword>Morbus Sudeck</keyword>
  <keyword>Causalgia</keyword>
  <keyword>Etoricoxib</keyword>
  <keyword>Polyneuropathy</keyword>
  <keyword>post herpetic neuralgia</keyword>
  <keyword>peripheral nerve injury</keyword>
  <keyword>radiculopathy</keyword>
  <keyword>Nervenverletzung</keyword>
  <keyword>postherpetische Neuralgie</keyword>
  <keyword>COX-2-Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Hyperalgesia</mesh_term>
    <mesh_term>Radiculopathy</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
    <mesh_term>Peripheral Nerve Injuries</mesh_term>
    <mesh_term>Causalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

